Phase 3 REPLATINUM study underway with CyNRGY platform lead candidate RRx-001 in Small Cell Lung Cancer

Focus on immune activation against cancer with emphasis on patient quality of life.

Toxicity to Tumors not to Patients

EpicentRx is developing new mechanisms of immunotherapy that act alone or in combination with other medicines to outsmart cancer with minimal toxicity across diverse patient populations and tumor types.

CyNRGY small molecule platform (RRx-001)

RRx-001, a next generation small molecule immunotherapeutic in the Phase 3 REPLATINUM trial to treat small cell lung cancer.

AdAPT cancer targeting virus platform (AdAPT-001)

AdAPT-001, a cancer targeting virus designed to infect cancer and eliminate a cancer defending protein that silences the immune system (TGF-beta)